Concussion — Adjunctive Supplement Considerations

Clinical Scenario All agents permitted — WADA 2026 Last reviewed: Apr 2026

TAF Scope — This Page: This is a clinical scenario cross-reference page. It does not provide concussion diagnosis guidance, management protocols, or return-to-play criteria. Those remain the responsibility of the treating clinician using validated tools (SCAT6 for healthcare professionals; available at bjsm.bmj.com).

This page identifies supplements with emerging evidence for adjunctive neuroprotective use alongside established concussion management. Each agent links to its individual TAF supplement entry for full governance detail.

Adjunctive Only: None of the agents below are recommended as routine clinical practice. They are adjunctive considerations only — used alongside, never instead of, established concussion management protocols. No athlete should progress through return-to-play while symptoms are pharmacologically suppressed.

Supplements with Emerging Neuroprotective Evidence

The following supplements have emerging or plausible evidence for adjunctive use in the post-concussion period. Evidence ratings use the TAF A–E system. Where evidence level and clinical recommendation diverge, a TAF note is provided. Full agent profiles — including WADA status, contamination risk, QA-confirmed products, dosing, and governance documentation prompts — are available in each individual supplement entry.

Supplement	Evidence Level	Indication in Concussion	TAF Note	Full Entry
Melatonin	B · Sleep D · Neuroprotection	Sleep regulation post-concussion; emerging neuroprotective role	PLAYGAME RCT negative for overall symptoms; sleep benefit in secondary analysis only	Soon →
Omega-3 / DHA	C · Neuroprotection	Neuronal membrane repair; anti-inflammatory; pilot RCT data	Strong preclinical; human data early but directionally promising	Soon →
Creatine	D · Metabolic support	Cerebral energy metabolism support; mitochondrial function	Strong biological plausibility; familiar safety profile in sport	Soon →
NAC	D · Antioxidant	Glutathione precursor; oxidative stress attenuation post-injury	Limited human sport-specific data; consistent mechanistic rationale	Soon →
Magnesium	C · Neuroprotection	NMDA receptor regulation; excitotoxicity attenuation	Evidence level overstates utility — inconsistent results across age groups	Soon →

Governance Considerations

Anti-Doping

All agents listed are not prohibited under WADA 2026. Contamination risk varies by supplement — batch-tested certified product required for all. Verify at nsf.org or Informed Sport before recommending.

Symptom Masking

None of the listed agents are known to mask neurological symptoms. No athlete should progress through return-to-play while symptoms are pharmacologically suppressed by any agent.

Documentation

Document any adjunctive supplement use in the athlete's medical record, including product name, batch number, and clinical rationale for use.

Concurrent Medications

Review interactions with any analgesics, anti-emetics, or sleep agents prescribed concurrently. See individual supplement entries for specific interaction data.

TAF Evidence Rating System: Ratings use the A–E system adapted from Oxford CEBM Levels of Evidence. A TAF note appears where the evidence level and clinical recommendation diverge. See the About page for full methodology.